<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2522304-B1" country="EP" doc-number="2522304" kind="B1" date="20140108" family-id="27379790" file-reference-id="318220" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146587774" ucid="EP-2522304-B1"><document-id><country>EP</country><doc-number>2522304</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-11190811-A" is-representative="NO"><document-id mxw-id="PAPP154849966" load-source="docdb" format="epo"><country>EP</country><doc-number>11190811</doc-number><kind>A</kind><date>20020322</date><lang>EN</lang></document-id><document-id mxw-id="PAPP234292577" load-source="docdb" format="original"><country>EP</country><doc-number>11190811.7</doc-number><date>20020322</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140550655" ucid="EP-02753826-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>02753826</doc-number><kind>A</kind><date>20020322</date></document-id></priority-claim><priority-claim mxw-id="PPC140554431" ucid="US-0209001-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>0209001</doc-number><kind>W</kind><date>20020322</date></document-id></priority-claim><priority-claim mxw-id="PPC140550782" ucid="US-10467702-A" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>10467702</doc-number><kind>A</kind><date>20020322</date></document-id></priority-claim><priority-claim mxw-id="PPC140549561" ucid="US-27853401-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>27853401</doc-number><kind>P</kind><date>20010323</date></document-id></priority-claim><priority-claim mxw-id="PPC140549904" ucid="US-35208502-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>35208502</doc-number><kind>P</kind><date>20020124</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130725</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989323855" load-source="docdb">A61K  35/12        20060101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323856" load-source="docdb">A61F   2/00        20060101AFI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323857" load-source="docdb">A61L  27/24        20060101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323858" load-source="docdb">A61L  27/36        20060101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323859" load-source="docdb">A61L  27/38        20060101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323860" load-source="docdb">A61L  27/56        20060101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323861" load-source="docdb">C12N   5/071       20100101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323862" load-source="docdb">C12N  11/02        20060101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323863" load-source="docdb">C12N  11/04        20060101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323864" load-source="docdb">C12N  11/08        20060101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323865" load-source="docdb">C12N  11/16        20060101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989323866" load-source="docdb">C12P  19/34        20060101ALI20130708BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989631838" load-source="docdb">C12N   5/02        20060101A I20060521RMUS        </classification-ipcr><classification-ipcr mxw-id="PCL1989651502" load-source="docdb">C12N   5/077       20100101A I20100814RMEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989624398" load-source="docdb" scheme="CPC">A61L  27/24        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989627689" load-source="docdb" scheme="CPC">A61L  27/3895      20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989633590" load-source="docdb" scheme="CPC">A61K  35/12        20130101 LA20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989634013" load-source="docdb" scheme="CPC">A61L  27/3817      20130101 FI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989638439" load-source="docdb" scheme="CPC">A61F2310/00365     20130101 LA20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989640923" load-source="docdb" scheme="CPC">A61L  27/56        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989641999" load-source="docdb" scheme="CPC">C12N   5/0655      20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989643426" load-source="docdb" scheme="CPC">A61L  27/3633      20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989645841" load-source="docdb" scheme="CPC">A61L  27/3843      20130101 LI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132367955" lang="DE" load-source="patent-office">Zusammensetzung und Verfahren zur Herstellung von biologischen Geweben und Gewebekonstrukten</invention-title><invention-title mxw-id="PT132367956" lang="EN" load-source="patent-office">Composition and methods for the production of biological tissues and tissue constructs</invention-title><invention-title mxw-id="PT132367957" lang="FR" load-source="patent-office">Composition et procédés pour la production de tissus biologiques et de constructions tissulaires</invention-title></technical-data><related-documents><relation type="division"><child-doc ucid="EP-11190811-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>11190811</doc-number><kind>A</kind><date>20020322</date></document-id></child-doc><parent-doc ucid="EP-02753826.3"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>02753826.3</doc-number><date>20020322</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR919508349" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>HISTOGENICS CORP</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919518303" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>HISTOGENICS CORPORATION</last-name></addressbook></applicant><applicant mxw-id="PPAR919511424" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>PURPOSE COMPANY LTD</last-name><address><country>JP</country></address></addressbook></applicant><applicant mxw-id="PPAR919531090" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>PURPOSE COMPANY LIMITED</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919524625" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>TARRANT LAURENCE J</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919543279" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>TARRANT, LAURENCE J.</last-name></addressbook></inventor><inventor mxw-id="PPAR919019989" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>TARRANT, LAURENCE J.</last-name><address><street>Suite 19, 116 Pleasant Street</street><city>Easthampton, MA 01027</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919546017" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>MIZUNO SHUICHI</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919509466" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>MIZUNO, SHUICHI</last-name></addressbook></inventor><inventor mxw-id="PPAR919019988" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>MIZUNO, SHUICHI</last-name><address><street>48A Harvard Avenue Apt B1</street><city>Brookline, MA 02446</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919516737" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>TOKUNO TOSHIMASA</last-name><address><country>JP</country></address></addressbook></inventor><inventor mxw-id="PPAR919546165" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>TOKUNO, TOSHIMASA</last-name></addressbook></inventor><inventor mxw-id="PPAR919019987" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>TOKUNO, TOSHIMASA</last-name><address><street>1-16-1 Chitosdai</street><city>Setagaya-ku, Tokyo 157-0071</city><country>JP</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919019991" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Histogenics Corporation</last-name><iid>100967020</iid><address><street>830 Winter Street, 3rd Floor</street><city>Waltham, MA 02451</city><country>US</country></address></addressbook></assignee><assignee mxw-id="PPAR919019992" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>Purpose Company Limited</last-name><iid>101396924</iid><address><street>201, Nishi Kashiwabara Shinden</street><city>Fuji-shi Shizuoka-ken 417-8505</city><country>JP</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919019990" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Kirkham, Nicholas Andrew</last-name><suffix>et al</suffix><iid>100040565</iid><address><street>Graham Watt &amp; Co. LLP St. Botolph's House 7-9 St. Botolph's Road</street><city>Sevenoaks Kent TN13 3AJ</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS549793103" load-source="docdb">AT</country><country mxw-id="DS549777838" load-source="docdb">BE</country><country mxw-id="DS549885118" load-source="docdb">CH</country><country mxw-id="DS549777967" load-source="docdb">CY</country><country mxw-id="DS549777839" load-source="docdb">DE</country><country mxw-id="DS549777968" load-source="docdb">DK</country><country mxw-id="DS549861252" load-source="docdb">ES</country><country mxw-id="DS549863554" load-source="docdb">FI</country><country mxw-id="DS549865877" load-source="docdb">FR</country><country mxw-id="DS549777840" load-source="docdb">GB</country><country mxw-id="DS549777977" load-source="docdb">GR</country><country mxw-id="DS549885119" load-source="docdb">IE</country><country mxw-id="DS549865882" load-source="docdb">IT</country><country mxw-id="DS549777978" load-source="docdb">LI</country><country mxw-id="DS549921193" load-source="docdb">LU</country><country mxw-id="DS549863555" load-source="docdb">MC</country><country mxw-id="DS549921194" load-source="docdb">NL</country><country mxw-id="DS549777979" load-source="docdb">PT</country><country mxw-id="DS549921195" load-source="docdb">SE</country><country mxw-id="DS549885120" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><description mxw-id="PDES63960210" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>FIELD OF THE INVENTION</b></heading><p id="p0001" num="0001">The present invention relates to compositions and methods for preparing tissues and tissue constructs. In particular, the invention recites compositions and methods which incorporate cells into biological matrices.</p><heading id="h0002"><b>BACKGROUND</b></heading><p id="p0002" num="0002">Vertebrate tissues and organs often fail to recover normal form and function when damaged and often fail (due to metabolic and / or mechanical trauma) to adequately integrate with a host when transplanted. In attempts to reconstruct tissues and organs; surgeons have implanted either living tissues or non-living materials in place of damaged or resected native anatomical structures . These traditional techniques have limitations. For example while autografts are histocompatible, the loss of tissue from the donor site often creates anatomical and / or physiological pathologies in the very same host. On the other hand, transplanted allografts and xenografts often provoke a pathological immune response which is proximal to the rejection of these grafts by the host.</p><p id="p0003" num="0003">Non-living transplant materials are of marginal utility in the repair and transplant of native tissues, tissue constructs, and organs. Specifically, transplanted non-living materials are especially subject to extrusion, infection, and scar tissue formation.</p><p id="p0004" num="0004">The use of bioengineered tissue as alternatives to transplanted native tissues and non-living materials has also been described. For example, <patcit id="pcit0001" dnum="US5902741A"><text>U.S. Pat. No. 5,902,741 to Purchio et al.</text></patcit> teaches a method for culturing cartilage tissue <i>in vitro</i> using a framework inoculated with a nutrient medium bearing cartilage cells or precursors. Similarly, <patcit id="pcit0002" dnum="US5928945A"><text>U.S. Pat. No. 5,928,945 to Selektar et al.</text></patcit> teaches a process for producing bioengineered neo-cartilage by applying fluid-flow shear flow stress to chondrocytes. In another example <patcit id="pcit0003" dnum="US6080194A"><text>U.S. Pat. No. 6,080,194 to Pachence et al</text></patcit> teaches a template for producing articular cartilage comprising a dense collagen matrix placed on the surface of the cartilage defect to prevent cell migration and vascular in-growth from the sub-chondral plate.</p><p id="p0005" num="0005">However, these compositions and methods (in the prior art) only approximate a fraction of the anatomical and physiological repertoire of the native tissue they are attempting to replace. More specifically, these shortcomings in the prior art may, in part, be attributed to the inability to uniformly seed, culture, and differentiate cells across the entire cross section<!-- EPO <DP n="2"> --> of a three-dimensional cellular support layer. What is needed, therefore, are transplantable tissue and tissue constructs that can support cells in their normal metabolic state and can anatomically and physiologically integrate with a host without provoking a pathogenesis.</p><p id="p0006" num="0006"><patcit id="pcit0004" dnum="US6171610B1"><text>US 6 171 610 B1</text></patcit> discloses a scaffold produced by a method, comprising:
<ol><li>a) providing, i) a sol-gel solution comprising suspended chondrocytes; ii) a sponge matrix;</li><li>b) introducing said sponge matrix into said solution under conditions such that said solution enters said sponge by capillary action and said chondrocytes contact said matrix so as to create a seeded device; and</li><li>c) treating said seeded device with said treatment means under conditions such that at least a portion of said solution solidifies within said device.</li></ol></p><p id="p0007" num="0007">The matrix is configured to be transplanted into a joint of a human being.</p><p id="p0008" num="0008"><patcit id="pcit0005" dnum="WO0102030A"><text>WO 01/02030 A</text></patcit> discloses a method to maintain chondrocytes differentiated in a three-dimensional tissue derived from natural tissue, useful for cartilage implants. The method comprises applying cyclic hydrostatic pressure.</p><p id="p0009" num="0009"><nplcit id="ncit0001" npl-type="b"><text>SMITH R L ET AL: "In vitro stimulation of articular chondrocyte mRNA and extracellular matrix synthesis by hydrostatic pressure", JOURNAL OF ORTHOPAEDIC RESEARCH, JOHN WILEY &amp; SONS, INC, NEEDHAM, MA, vol. 14, no. 1, 1 January 1996 (1996-01-01), pages 53-60</text></nplcit>, discloses a scaffold produced by a method comprising:
<ul><li>a- providing a solution comprising chondrocytes;</li><li>b- seeding the chondrocytes on a device to obtain a high density monolayer on a seeded device;</li><li>c- treating said seeded device under conditions comprising subjecting said device seeded with chondrocytes to culturing with a cyclic hydrostatic pressure of 10 MPa at 1 Hz for 4 h.</li></ul></p><p id="p0010" num="0010">The cyclic hydrostatic pressure simulates the physiologic hydrostatic pressure and activates the chondrocytes.</p><heading id="h0003">SUMMARY OF THE INVENTION</heading><p id="p0011" num="0011">The present invention provides an implantable multi-layered construct prepared by a process comprising the steps of:
<ol><li>(a) providing an implantable-multilayered structure comprising:
<ol><li>(i) an integration layer;</li><li>(ii) a cellular support layer comprising a sponge matrix and being operably linked to the integration layer;</li></ol></li><li>(b) introducing a solution comprising suspended cells, which are chondrocytes, into said multilayered structure to create a seeded device; and</li><li>(c) culturing said seeded device under conditions comprising cyclic hydrostatic pressure followed with a resting phase at atmospheric pressure.</li></ol></p><p id="p0012" num="0012">In one embodiment the present invention contemplates a composition comprising a first integration layer; a second cellular support layer (comprising a matrix) operably linked to said first integration layer wherein said support layer is seeded with cells (suspended in a gel), and a third protective layer operably linked to said first and second layers.</p><p id="p0013" num="0013">It is not intended that the present invention be limited to a composition comprising a multi-layered system have a specific number of layers. In one embodiment, said multi-layered system comprises two layers. In a preferred embodiment, said multi-layered system comprises three layers. In another embodiment, said multi-layered system comprises more than three layers.</p><p id="p0014" num="0014">It is not intended that the present invention be limited to a specific method for constructing a cellular support matrix. Japanese Patent No. <patcit id="pcit0006" dnum="JP6022744B"><text>6,022,744</text></patcit> entitled, "Collagen Carrier For Cell Culture" describes the preparation of a matrix suitable for use a cellular support layer described in the present invention.</p><p id="p0015" num="0015">It is not intended that the gel element of said cell support layer be limited to a single composition. In one embodiment, said gel element comprises gelatin. In another embodiment, said gel element comprises collagen. In a preferred embodiment, said gel element comprises Type I collagen.</p><p id="p0016" num="0016">In a preferred embodiment, said<!-- EPO <DP n="3"> --><!-- EPO <DP n="4"> --> chondrocytes are harvested from connective tissue. In a preferred embodiment, said connective tissue is cartilage.</p><p id="p0017" num="0017">In one embodiment, the present invention describes methods for preparing tissues or tissue constructs using a multi-layered system that includes a cellular support matrix seeded with living cells directly isolated and / or expanded from viable tissue. In a preferred embodiment, the present invention contemplates a method providing a cellular support matrix, a gel, and cells; mixing said cells with said gel to form a cell suspension; and contacting said cell suspension with said cellular support matrix to create a cell seeded matrix.</p><p id="p0018" num="0018">In another embodiment, the present invention further comprises applying heat to said cell-seeded matrix under conditions that said gel is cured into a substantially solid form, thereby, forming a heat cured cell-seeded matrix.</p><p id="p0019" num="0019">In another embodiment, the present invention further comprises culturing said heat-cured cell-seeded matrix under conditions comprising constant or cyclic hydrostatic pressure, wherein said cellular support matrix consists essentially of porous Type I collagen.</p><p id="p0020" num="0020">In another embodiment, the present invention contemplates a treatment, of said seeded device, comprising heating in the absence of carbon dioxide.</p><p id="p0021" num="0021">In one embodiment of the present invention, the sponge matrix is configured to be transplanted into a joint of a human being.</p><p id="p0022" num="0022">In one embodiment of the present invention, the chondrocyte suspension solution comprises neutralized aqueous Type I collagen.</p><p id="p0023" num="0023">In another embodiment the present invention further comprises, after step (c) above, culturing said chondrocytes under conditions such that said chondrocytes elaborate gene products associated with the extracellular matrix. In one embodiment said culturing is performed under pressure greater than 1 atmosphere of pressure. In another embodiment,<!-- EPO <DP n="5"> --> said culturing is performed under constant or cyclic hydrostatic pressure wherein said cyclic hydrostatic pressure is in a range of approximately 0.01 - 10.0 MPa at 0.5 Hz. In another embodiment, said cyclic hydrostatic pressure is in a range of 0.5 - 5.0 MPa at 0.5 Hz. In a preferred embodiment, said cyclic hydrostatic pressure is approximately 3.0 MPa of pressure at 0.5 Hz. In one embodiment the duration of said cyclic pressure is 1 - 30 days. In another embodiment, the duration of said cyclic pressure is 5 - 8 days. In a preferred embodiment, the duration of said cyclic pressure is approximately 6 days.</p><p id="p0024" num="0024">In one embodiment the present invention the resting phase is of a duration in the range of 1 - 60 days. In one embodiment, the duration of said resting phase is in the range of 4 - 21 days. In a preferred embodiment, said resting phase is approximately 12 days.</p><p id="p0025" num="0025">In one embodiment of the present invention, said chondrocytes suspension solution is at least partially gelled.</p><p id="p0026" num="0026">In one embodiment of the present invention, the treatment means comprises a culture chamber. In another embodiment the treatment comprises heating in the absence of carbon dioxide.</p><p id="p0027" num="0027">In one embodiment of the present invention the sponge matrix comprises Type I collagen configured to be transplanted into a joint of a human being.</p><p id="p0028" num="0028">In another embodiment, the present invention further comprises, after step (c), culturing said chondrocytes under conditions such that said chondrocyte elaborate gene products associated with the extracellular matrix.</p><p id="p0029" num="0029">In one embodiment of the present invention, said culturing is performed under pressure of 1 atmosphere or greater. In another embodiment, said culturing is performed under constant or cyclic hydrostatic pressure wherein said cyclic hydrostatic pressure is in a range of approximately 0.01 - 10.0 MPa at 0.5 Hz. In another embodiment, said cyclic hydrostatic pressure is in a range of 0.5 - 5.0 MPa at 0.5 Hz. In a preferred embodiment, said cyclic hydrostatic pressure is approximately 3.0 MPa of pressure at 0.5 Hz.. In one<!-- EPO <DP n="6"> --> embodiment the duration of said cyclic pressure is 1 - 30 days. In another embodiment, the duration of said cyclic pressure is 5 - 8 days. In a preferred embodiment, the duration of said cyclic pressure is approximately 6 days.</p><p id="p0030" num="0030">In one embodiment the present invention contemplates a resting phase (following exposure to cyclic pressure). In one embodiment, the duration of said resting phase is in the range of 1 - 60 days. In another embodiment, the duration of said resting phase is in the range of 4 - 21 days. In a preferred embodiment, said resting phase is approximately 12 days.</p><p id="p0031" num="0031">It is not intended that the present invention be limited to a situation wherein said chondrocytes suspended in a sol-gel solution. It is not intended that the present invention be limited to any specific degree of gellation for said chrondrocyte containing sol-gel solution.</p><p id="p0032" num="0032">It is not intended that the present invention be limited to a situation wherein the entire chondrocytes suspension solution solidifies. That is to say, it is sufficient that a significant portion of the solution solidifies, thereby in one embodiment, substantially immobilizing the suspended cells within a seeded matrix.</p><p id="p0033" num="0033">In one embodiment, the present invention contemplates a system, comprising: i) a cellular support layer configured to permit growth of cells in three-dimensions, said cellular support layer having an integrative side and a functional side, and wherein said cellular support is seeded with at least one cell type to create seeded cells; ii) an integration layer contacting said integrative side of said cellular support layer, wherein said integration layer is configured to be insertable into tissue; and iii) a protective layer contacting said functional side of said cellular support layer, said protective layer configured to protect said seeded cells from the effects of blood-borne agents.</p><p id="p0034" num="0034">In one embodiment of the present invention, said blood-borne agents are clotting factors, cytokines, and / or cytotoxic cells. In one embodiment of the present invention, said seeded cells are in contact with a nutrient fluid. In another embodiment of the present invention, said integration layer is configured to be insertable into tissue following surgery.</p><p id="p0035" num="0035">In one embodiment of the present invention contemplates a method for inserting a system comprising: i) a cellular support layer configured to permit growth of cells in three-dimensions, said cellular support layer having an integrative side and a functional side, and wherein said cellular support is seeded with at least one cell type to create seeded cells; ii) an integration layer contacting said integrative side of said cellular support layer, wherein said integration layer is configured to be insertable into tissue; and iii) a protective layer contacting said functional side of said cellular support layer, said protective layer configured<!-- EPO <DP n="7"> --> to protect said seeded cells from the effects of blood-borne agents and into the tissues of a patient. In another embodiment, the insertion of the system into the patient follows surgery on said patient.</p><heading id="h0004"><b>DESCRIPTION OF THE DRAWINGS</b></heading><p id="p0036" num="0036"><ul><li><figref idrefs="f0001">Figure 1</figref> projects data on the effect of cyclic hydrostatic pressure, as compared to static atmospheric pressure, on glycosaminoglycan (GAG) production by chondrocytes cultured within the TESS matrix. Specifically, this figure shows that there is a 300% increase (p &lt; 0.001) in GAG production in TESS matricies in the test group (3.0 MPa CHP at 0.5 Hz) than in the TESS matricies in the control group (atmospheric pressure only).</li><li><figref idrefs="f0002">Figure 2A</figref> is a photomicrograph presenting the elaboration of Safranin-O staining of extracellular matrix by chondrocytes, cultured under static atmospheric pressure (control group), within the TESS matrix. In this figure the honeycomb sponge element of the cellular support matrix (e.g. the TESS matrix) is labeled "HC" and an area of extracellular matrix (elaborated by the cultured chondrocytes) is labeled with an "*".</li><li><figref idrefs="f0003">Figure 2B</figref> is a photomicrograph presenting the elaboration of Safranin-O staining of extracellular matrix by chondrocytes, cultured under cyclic hydrostatic pressure (test group), within the TESS matrix. In this figure the honeycomb sponge element of the cellular support matrix (e.g. the TESS matrix) is labeled "HC" and an area of extracellular matrix (elaborated by the cultured chondrocytes) is labeled with an "*".</li><li><figref idrefs="f0004">Figure 3A</figref> is another photomicrograph presenting the elaboration of Safranin-O staining extra cellular matrix by chondrocytes, cultured under static atmospheric pressure (control group), within the TESS matrix. In this figure the honeycomb sponge element of the cellular support matrix (e.g. the TESS matrix) is labeled "HC" and an area of extracellular matrix (elaborated by the cultured chondrocytes) is labeled with an "*".</li><li><figref idrefs="f0005">Figure 3B</figref> is a another photomicrograph presenting the elaboration of Safranin-O staining of extracellular matrix by chondrocytes, cultured under cyclic hydrostatic pressure (test group), within the TESS matrix. In this figure the honeycomb sponge element of the cellular support matrix (e.g. the TESS matrix) is labeled "HC" and an area of extracellular matrix (elaborated by the cultured chondrocytes) is labeled with an "*".</li><li><figref idrefs="f0006">Figure 4</figref> illustrates data on the effect of cyclic hydrostatic pressure, as compared to static atmospheric pressure, on glycosaminoglycan (GAG) production by chondrocytes cultured with the TESS matrix. Specifically, this figure shows that there is a 132% increase<!-- EPO <DP n="8"> --> (p&lt;0.006) in GAG production in TESS matricies in the test group (3.0 Mpa CHP at 0.5 Hz) compared to TESS matricies in the control group (atmospheric pressure only).</li></ul></p><heading id="h0005"><b>DEFINITIONS</b></heading><p id="p0037" num="0037">As used herein, the term "tissue" refers to a collection of similar cells and the intercellular substances surrounding them. It will be appreciated by those of ordinary skill in the art that there are four basic tissue types in the body, 1) epithelium; 2) connective tissue including blood, bone and cartilage; 3) muscle; and 4) nerve.</p><p id="p0038" num="0038">As used herein, the term "neo-tissue" refers to a composition, comprising cells, that approximates the form and function of a native tissue <i>in situ.</i></p><p id="p0039" num="0039">As used herein, the term "neo-organ" refers to a synthetic composition, comprising cells, that approximates the form and function of a native organ <i>in situ.</i></p><p id="p0040" num="0040">As used herein, the term "neo-cartilage" refers to a plurality of chondrocytes in a transitional state of histogenesis. This transitional state of histogenesis is characterized by the elaboration of gene products associated with the extracellular matrix (i.e. GAG's) and a morphology comprising partial encapsulation into lacunae. In one embodiment, this neo-cartilage is manufactured by Histogenics Corporation (Easthampton, MA) under the trademark NEOCART.</p><p id="p0041" num="0041">As used herein, the term "tissue construct" refers to a substantially avascular mixed population of cells that (in a preferred embodiment) is propagated in a tissue culture system including, but not limited to, the TESS tissue processor.</p><p id="p0042" num="0042">The term "neo-tissue construct" refer to tissue constructs formed <i>de novo</i> from cells or tissue by the methods of the present invention.</p><p id="p0043" num="0043">As used herein, the term "native environment" refers to the <i>in situ</i> biological environment supporting a native tissue or a tissue construct.</p><p id="p0044" num="0044">As used herein, the term "biocompatible" refers to compositions (<i>e.g</i>. cells, tissues, matrices, etc.) that do not substantially disrupt the normal biological functions of other compositions to which they contact. For example, the present invention contemplates a composition comprising a multi-layered system having a physical and chemical structure which is biocompatible with the cells and tissue produced by said system (<i>e.g</i>. neo-tissues), and which is also biocompatible with the cells or tissues into which said system (and its cells or tissue) is delivered. In selected embodiments, the present invention also contemplates biocompatible materials that are both biodegradable and non-biodegradable.<!-- EPO <DP n="9"> --></p><p id="p0045" num="0045">As used herein, the term "matrix" refers to a composition comprising a plurality of pores dividing free space into partially enclosed interstices wherein said interstices are in fluidic communication. One type of matrix is a "sponge matrix" comprising a matrix that takes up fluid by capillary action. In selected embodiments, the present invention contemplates a composition comprising a cellular support layer, wherein said cellular support layer comprises a collagenous sponge matrix.</p><p id="p0046" num="0046">As used herein, the term "TESS matrix" refers to a commercial (a proprietary composition manufactured by Koken Company LTD., Toyko Japan) embodiment of the cellular support layer described in the present invention.</p><p id="p0047" num="0047">As used herein, the term "pore size" refers to the average cross-sectional dimension of interstices in a matrix.</p><p id="p0048" num="0048">As used herein, the term "functional surface," refers to the surface that is directed toward a region of a cell, tissue or organ carrying out at least one function. For example, in a system for producing cartilage, the term "functional surface" refers to the surface facing the synovium when the system is implanted in a host. Likewise, in a system for producing oral mucosa, the term "functional surface" refers to the surface facing the inside of the mouth once the system is implanted into a host.</p><p id="p0049" num="0049">As used herein, the term "donor" refers to a human or non-human from whom cells, tissues, blood, or an organ is taken for transplantation.</p><p id="p0050" num="0050">As used herein, a "host" refers to an individual (whether human or non-human) into whom cells, tissue, blood, or organs are transplanted. For example, the present invention contemplates methods in which cells (<i>e.g</i>. chondrocytes) are taken from a donor for multiplication <i>in vitro</i> and transplantation into a host (whether the donor and host are the same individual, or different individuals).</p><p id="p0051" num="0051">As used herein, the word "chondrocyte" refers to a specific type of cartilage cell. <i>In vivo</i>, these cells are characterized by distinct morphologies and physiologies (observed <i>in situ</i>) as compared to the <i>in vitro</i> morphologies and physiologies (as observed in tissue culture) for these same cells. For example, chondrocytes harvested from adult mammalian trochlea are substantially non-dividing and elaborate substantially no extracellular matrix (i.e. GAG's). In contrast substantially quiescent chondrocytes isolated from adult mammalian trochlea are activated in vitro (for example when placed in tissue culture) such that a majority of these cultured cell divide and produce, in vitro, gene products associated with the extracellular matrix (i.e. GAG's).<!-- EPO <DP n="10"> --></p><p id="p0052" num="0052">As used herein, the term "suspended chondrocytes" refers to any number of chondrocytes in a fluid. In a preferred embodiment said fluid comprises aqueous Type I collagen.</p><p id="p0053" num="0053">As used herein, the term "delivering tissue" refers to the process of introducing, inserting, injecting or transplanting cells or tissue from a donor into a host. For example, the present invention contemplates methods wherein tissue grown in the multi-layered system of the present invention (<i>i.e</i>. neo-tissue) is delivered into a host at, for example, the site of a lesion (<i>i.e</i>. target lesion).</p><p id="p0054" num="0054">As used herein, the term "cyclic hydrostatic pressure" (and the abbreviation "CHP") refers to the application of repeated (e.g. two or more) periods of applied hydrostatic pressure (within a defined loading interval) which preferably create a sine wave form of measured pressure. In a preferred embodiment said CHP is 3.0 MPa at 0.5 Hz.</p><p id="p0055" num="0055">As used herein, the term "constant pressure" refers to the application of a substantially non-fluctuating (e.g. plus or minus 20% or less, or more preferably 5% or less) or non-cyclic pressure load over a period of time.</p><p id="p0056" num="0056">As used herein, the term "loading" or "loading interval" refers to a period of applied CHP load followed by a return to ambient pressure (e.g. wherein no external pressure is applied).</p><p id="p0057" num="0057">As used herein, the term "resting phase" refers to a variable length of time wherein cells are maintained in culture at approximately atmospheric pressure after exposure to or culturing under cyclic hydrostatic pressure.</p><p id="p0058" num="0058">As used herein, the term <i>"de novo</i> formation" refers to the production of cells (<i>e.g.</i> chondrocyte, fibroblasts, fibrochondrocytes, tenocytes and osteoblasts) or tissues (<i>e.g</i>. cartilage connective tissue, fibrocartilage, tendon, and bone) within a support structure (<i>e.g</i>. multi-layered system, scaffold or collagen matrix.</p><p id="p0059" num="0059">As used herein the term, "Type I collagen" is characterized by two alpha 1(I) chains, and one alpha2(I) chains (heterotrimeric collagen). The alphal(I) chains are approximately 300nm long. Type I collagen is predominantly found in bone, skin (in sheet-like structures), and tendon (in rope-like structures). Type I collagen is further typified by its reaction with the protein core of another connective tissue component known as a proteoglycan.</p><p id="p0060" num="0060">As used herein, the term "Type II collagen" collagen is characterized by three identical alphal(II) chains (homotrimeric collagen) present on chromosome 12. Type II collagen in cartilage presents as thin fibrils in a lose mesh, strongly interacting with other components (especially proteoglycans). Type II collagen is covalently cross-linked to type<!-- EPO <DP n="11"> --> IX collagen and other FACIT collagens, that help in the formation of type II collagen. This molecule is also able to bind and interact with integrin and decorin molecules.</p><p id="p0061" num="0061">As used herein, "neutralized aqueous Type I collagen" refers to Type I collagen without charge.</p><p id="p0062" num="0062">As used herein, "MMP" refers to "matrix metalloproteinase". MMP associated with cartilage degeneration in a diseased joint. MMP may be further distinguished as MMP-1, MMP-2, MMP-9, etc.</p><p id="p0063" num="0063">As used herein, the term "MPa" means MegaPascal. One MPa is equal to 145 psi.</p><p id="p0064" num="0064">As used herein, the term "mandrel" refers to a tapered or cylindrical axle, spindle, or arbor that serves as a core around which material may be cast molded, forged, bent, or otherwise shaped.</p><p id="p0065" num="0065">As used herein, the term "epithelial tissue" refers to the cellular (typically avascular) layer covering all the free surfaces, cutaneous, mucous, and serous, including the glands and other structures derived there from. Epithelial tissue present squamous, cuboidal, and / or columnar cells upon histological examination. In addition, epithelial tissue may be described as simple, stratified or pseudostratified.</p><p id="p0066" num="0066">As used herein, the term "connective tissue" refers to tissue that protects and supports the body and its organs, and tissues that bind organs together. Examples of such tissues include (but are not limited to) mesenchyme, mucous connective, areolar (loose), adipose, reticular, elastic, collagenous, bone, blood, or cartilage tissue (<i>e.g</i>. hyaline, fibro, and elastic cartilage).</p><p id="p0067" num="0067">As used herein, the term "muscular tissue" refers to tissue that is characterized by the ability to contract upon stimulation and may be categorized as skeletal, cardiac, and smooth.</p><p id="p0068" num="0068">As used herein, the term "nervous tissue" refers to tissue (comprising nerve fibers, dendrites, and supporting tissues) that initiate and transmit nerve impulses.</p><p id="p0069" num="0069">As used herein, the terms "membrane tissue" and "membranous tissue" refer to a combination of epithelial tissue and connective tissue that forms a membrane. Examples of such membranes include (but are not limited to) mucous, serous, cutaneous, and synovial membranes.</p><p id="p0070" num="0070">As used herein the term, "sol-gel solution" refers to a colloidal suspension which may transition from a liquid (sol) to a more solid material (gel). In a preferred embodiment, the "sol" is a suspension of aqueous collagen that is transitioned, by heat treatment, into a gel.</p><p id="p0071" num="0071">As used herein, the term "gel" or "gelled" refers to the state of matter between liquid and solid. As such, a "gel" has some of the properties of a liquid (i.e., the shape is resilient<!-- EPO <DP n="12"> --> and deformable) and some of the properties of a solid (i.e., the shape is discrete enough to maintain three dimensions on a two dimensional surface.).</p><p id="p0072" num="0072">As used herein, the term "partially gelled" refers to the state of matter between liquid and solid such that a substance demonstrates more of the properties of a liquid (i.e., the shape is resilient and deformable) and fewer of the properties of a solid (i.e., the shape is discrete enough to maintain three dimensions on a two dimensional surface.).</p><p id="p0073" num="0073">As used herein the term "solidifies" or "solidified" refers to any process by which a substance is made solid, compact, or hard.</p><p id="p0074" num="0074">As used herein the term "partially solidifies" or "partially solidified" refers to any process by which a substance is made to some degree more solid, compact, or hard as compared to the substance acted on.</p><p id="p0075" num="0075">As used herein, the words "cure" or "cured" refers the application of a chemical or physical process to further solidify a gel.</p><p id="p0076" num="0076">As used herein, the term "treatment means" refers to any device that can regulate temperature, atmospheric pressure, and / or gas saturation.</p><p id="p0077" num="0077">As used herein, the term "seeded device" refers to a matrix containing any number of cells. In a preferred embodiment, said seeded device comprises chondrocytes disposed within a collagenous sponge matrix.</p><p id="p0078" num="0078">As used herein, the term "elaborate gene products" refers to the production of peptides and/or proteins by a cells. In a preferred embodiment, chondrocytes produce proteins associated with the extracellular matrix of cartilage (including but not limited to GAGs).</p><heading id="h0006"><b>DETAILED DESCRIPTION OF THE INVENTION</b></heading><p id="p0079" num="0079">The present invention relates to compositions and methods for the preparation of neo-tissues and tissue constructs. In preferred embodiments, the invention relates to the construction of a multi-layered biological structure (e.g. any three dimensional form) that includes at least one matrix layer seeded with living cells.</p><heading id="h0007"><b>I. GENERAL DESIGN OF A SYSTEM FOR THE PRODUCTION OF TISSUES AND TISSUE CONSTRUCTS</b></heading><p id="p0080" num="0080">The present invention provides a composition comprising a matrix which contains cells, originally harvested from an <i>in situ</i> organ or tissue, that have been subsequently expanded (<i>via</i> cell culture <i>in vitro</i>) prior to seeding within said matrix. In one embodiment<!-- EPO <DP n="13"> --> this composition, comprising a seeded matrix, is placed (like a cassette) into a tissue culture apparatus (in one example a tissue processor) such that the cells disposed within said system may expand in number and / or differentiate. Said cells are chondrocytes which multiply and differentiate when cultured under conditions including cyclic hydrostatic pressure.</p><p id="p0081" num="0081">The present invention is not limited to a specific configuration. In one embodiment, however, the present invention is a system comprising two layers.</p><p id="p0082" num="0082">The cellular support layer provides a platform which contains the cells seeded into the system and provides support for said cells as they: a) divide and differentiate (in a tissue culture apparatus) into a neo-tissue and b) when said system is implanted into a host.</p><p id="p0083" num="0083">The integration layer protects the neo-tissue as it divides, <i>ex vivo,</i> in a tissue culture apparatus. Once said neo-tissue is implanted into a host, the integration layer is oriented to oppose a native tissue surface of said host, thereby, exposing said neo-tissue to the milieu, including humoral factors (e.g. hormones and trophic factors), at the transplant site.</p><p id="p0084" num="0084">In some embodiments, the system also comprises a protective layer which substantially encapsulates the cellular support layer and the integration layer. The systems multi-layered design may be fabricated into a variety of forms. In one embodiment, the system may be a sheet. In another embodiment, the system can be formed to approximate the three-dimensional structure of a tissue or organ as observed <i>in vivo</i> including, but not limited to tubes, ellipsoids, and claviforms.</p><p id="p0085" num="0085">The neo-tissues (or "products") propagated according to the methods recited in the present invention substantially replicate native tissues. Specifically, the systems and methods of the present invention produce tissues that substantially reproduce the anatomy and physiology of native tissues. In one embodiment, the neo-tissues recited in the present invention are propagated from cell originally harvested from intended host (e.g. are autologous). In some embodiments the integration and cellular support layers of the present invention are biodegradable. In these embodiments, the non-cellular components of the system biodegrade such that, after implantation into a host, only the neo-tissue is integrated into the host.</p><p id="p0086" num="0086">As described above the multi-layered system comprises at least two layers, a cellular support layer and an integration layer. In selected embodiments, the system also incorporates a protective layer. Each of these layers is described more fully below. However, the present invention also contemplates the incorporation supplementary layers into the system. These<!-- EPO <DP n="14"> --> supplementary layers may contain a variety of trophic factors including, but not limited to, epidermal growth factor (EGF), transforming growth factor β (<i>e.g</i>. TGF β-1, TGF β-2, etc.), platelet derived growth factor (<i>e.g</i>. PDGF-AA, PDGF-AB and PDGF-BB), fibroblast growth factors (FGF), insulin-like growth factors (IGF), tumor necrosis factors (TNF), colony stimulating factors (CSFs), nerve growth factors (NGF), connective tissue growth factor (CTGF), brain-derived neurotropic factor (BDNF), ciliary neurotrophic factor (CNTF), pro-angiogenic or anti-angiogenic factors, and other therapeutic agents including, but not limited to, cytokines, interleukins (<i>e.g</i>. IL-1, IL-2) or other co-factors such as heparin or calmodulin, antibiotics, anti-neoplastic agents, and anti-bacterials, to further stimulate or control tissue remodeling, or to control sepsis.</p><p id="p0087" num="0087">In other embodiments, such supplementary layers may provide ontogenic or morphogenic factors such as, bone morphogenic proteins (BMP 1-8); hedgehog (hh) family gene products; Hox family gene products; Pax family gene products; Notch gene products; osteoprotegerin; and osteoprotegerin binding proteins.</p><p id="p0088" num="0088">It is important to note that although the general design of the system of the present invention provides for a system comprising more than one layer, the present invention also contemplates embodiments comprising only the cellular support layer.</p><heading id="h0008"><b>II. THE COMPONENTS OF THE MULTI-LAYERED SYSTEM</b></heading><heading id="h0009"><b>1. The Cellular Support Layer (and "TESS Matrix")</b></heading><p id="p0089" num="0089">The cellular support layer of the present invention (in a specific commercial embodiment referred to as the "TESS matrix") comprises a matrix that facilitates the three-dimensional propagation of tissue and tissue constructs. The function of the cellular support layer is, in part, to provide a growth platform for cells (in one example chondrocytes). Desirable features of the cellular support layer include (but are not limited to) biocompatibility, hydrophilicity, and neutral charge. In one embodiment, the cellular support layer comprises a matrix (or honeycomb-like lattice) fabricated substantially from Type I collagen. In one preferred embodiment said honeycomb-like Type I collagen matrix is referred to as the "TESS matrix".</p><p id="p0090" num="0090">It is not intended that this cellular support layer be limited to any specific material or formulation. For example, the matrix described in Japanese Patent No. <patcit id="pcit0007" dnum="JP6022744B"><text>6,022,744</text></patcit> is suitable for use as a cellular support layer as described in the present invention. This matrix is prepared by gelling an acidic aqueous collagen solution with ammonia gas to form a collagen<!-- EPO <DP n="15"> --> gel and then freeze drying said gel to evaporate substantially all to the water, thereby, forming a substantially porous dried matrix.</p><p id="p0091" num="0091">In one example, 300 grams of a 1% aqueous atelocollagen solution (maintained at pH 3.0) is poured into a 10 x 20 cm tray. This tray is then placed in a 5 liter container. A 50 ml open container containing 30ml of a 3% aqueous ammonia solution is then placed next to the tray, in the 5 liter chamber, containing 300 grams of said 1% aqueous solution of atelocollagen. The 5 liter container (containing the open trays of atelocollagen and ammonia) is then sealed and left to stand at room temperature for 12 hours. During this period the ammonia gas released from the open container of aqueous ammonia, and confined within the sealed 5 liter container, is reacted with the aqueous atelocollagen, thereby, gelling said aqueous solution of atelocollagen.</p><p id="p0092" num="0092">This collagenous gel is then washed with water overnight and, subsequently, freeze-dried to yield a sponge like matrix. This freeze dried matrix is then cut into squares, sterilized, and stored under a sterile wrap.</p><p id="p0093" num="0093">The present invention contemplates matrices prepared according to other protocols. In one embodiment, the matrix prepared according to the protocol set out in <patcit id="pcit0008" dnum="US5206028A"><text>U.S. Patent No. 5,206,028 to Li </text></patcit>will be used. In another embodiment, the collagen matrices prepared according to the protocols set out in <patcit id="pcit0009" dnum="US5656492A"><text>U.S. Patent No. 5,656,492 to Glowacki et al.</text></patcit> will be used.</p><p id="p0094" num="0094">The pore size of these collagen matrices may be adjusted by varying the dispersion pH, collagen concentration and the lyophilization cycle (<i>e</i>.<i>g</i>. freezing time, temperature range and cycle time). See, <patcit id="pcit0010" dnum="US4522753A"><text>U.S. Patent No. 4,522,753 to Yannas et al.</text></patcit>. While it is not intended that the present invention be limited to any specific mechanism, adjustment to pore size can be advantageous in promoting the even distribution of cells with different morphologies.</p><p id="p0095" num="0095">For example, chondrocytes cultured in a Type I collagen matrix show increased infiltration into said matrix when the average pore size of said matrix was greater than 100 micrometers. See, <patcit id="pcit0011" dnum="US6080194A"><text>U.S. Patent No. 6,080,194 to Pachence et al</text></patcit>. While it is not intended that the support layer of the present invention be limited to a specific pore size, in one embodiment of the present invention said pore size is in a range of approximately 50 - 500 micrometers. In another embodiment, the pore size is in a range of 100 - 300 micrometers. In another embodiment the pore size is approximately 200 micrometers.<!-- EPO <DP n="16"> --></p><p id="p0096" num="0096">It is not intended that the present invention be limited to a cellular support layer comprising Type I collagen. In other embodiments, the cellular support layers of the system are composed of other materials, including (but not limited to): other collagens such as Type II and Type IV collagens; cell-contracted collagen gels containing other components of the extra-cellular matrix such as proteoglycans, glycosaminoglycans, glycoproteins (<i>e</i>.<i>g</i>. fibronectin, laminin, etc.); elastin and/or bioactive peptide growth factors or cytokines; other biopolymers such as fibrin; synthetic biodegradable fibers made from such polymers as polylactic or polyglycolic acids, polycaprolactones, or polyamino acids, or their copolymers; and construct structures comprising collagen and polylactic acid.</p><heading id="h0010"><b>2. Gel Component</b></heading><p id="p0097" num="0097">In a preferred embodiment of the present invention, the cellular support matrix of the present invention acts like a sponge that wicks up (and evenly distributes throughout the interstices of the matrix) cells suspended in a sol-gel solution wherein said sol-gel solution is in its sol state. It is not intended that the present invention be limited to a specific type of sol-gel. However, preferred characteristics of this sol-gel include, but are not limited to, a viscosity (as a sol) that promotes easy mixing of cells under conditions such that only nominal shear forces are required to mix said cells with said gel. In a preferred embodiment this sol-gel is substantially composed of Type I collagen and is available commercially (e.g. VITROGEN produced by Cohesion Corporation of Palo Alto, CA.). VITROGEN is a purified (i.e. 99.9% pure) pepsin-solubilized bovine dermal collagen dissolved in 0.012N HCl and maintained as a sterile solution.</p><p id="p0098" num="0098">Another preferred characteristic of this sol-gel is the ability to be cured (or transition) into a solid form. Said solid form being characterized by a substantial inability to be freely poured or mixed. It is not intended that the present invention be limited to any specific mechanism for curing said sol-gel into a solid (e.g. gel) form. In one embodiment, said curing comprises the application of heat. In a preferred embodiment, the sol-gel is cured by the application to a temperature of approximately 37°C. In other embodiments said sol-gel may be cured into a substantially solid form through by exposure to chemicals or ultraviolet radiation.</p><p id="p0099" num="0099">In another embodiment, the present invention contemplates the use of polypeptide carrier gels.<!-- EPO <DP n="17"> --></p><heading id="h0011"><b>3. The Integration Layer</b></heading><p id="p0100" num="0100">The present invention also contemplates a support matrix, seeded with cells, further comprises an integration layer. The integration facilitates the incorporation (<i>in site</i>) of said support matrix, seeded with cells, into a lesion or defect in the body. In one embodiment, the integration layer is contacted with an organ or tissue <i>in situ.</i> That is to say, the integration layer forms an interface between the (surgically) introduced support matrix seeded with cells and the native <i>in situ</i> tissue or organ of a recipient.</p><p id="p0101" num="0101">Depending upon the particular type of cells seeded in the support matrix and the tissue into which said cells will be incorporated, the integration layer may provide different functions. In one embodiment the protective layer shields the implanted cell seeded matrix from endocrine or paracrine signals produced by the native tissue of the host. In another embodiment the integration layer may be configured to facilitate the transmission of endocrine or paracrine signals from the native tissue of the host to the implanted cell seeded matrix.</p><p id="p0102" num="0102">It is not intended that the present invention be limited to any specific mechanism of action for the integration layer. In one embodiment, the integration layer prevents the infiltration of blood vessels and unwanted cells from underlying bone tissue into a chondrocyte seeded matrix implanted into an articulating joint of a host.</p><p id="p0103" num="0103">In preparing the integration layer of the present invention, a dense collagen barrier can be prepared according to the procedure presented in <patcit id="pcit0012" dnum="US5206028A"><text>U.S. Patent No. 5,206,028</text></patcit>. A porous collagen matrix, having a thickness of about 4 mm to 10 mm, is hydrated using a humidity-controlled chamber (with a relative humidity of 80% at 25°C) for 60 minutes. The collagen material is compressed between two Teflon sheets to a thickness of less than 0.2 mm. The compressed material is then cross-linked in a solution of 0.5% formaldehyde, 1% sodium bicarbonate at pH 8 for 60 minutes. The cross-linked membrane is then rinsed thoroughly with water, and freeze-dried for about 48 hours. The dense collagen barrier has an inner construction of densely packed fibers that are intertwined into a multi-layer structure.</p><p id="p0104" num="0104">In another embodiment, the integration layer is prepared from collagen-based dispersions or solutions that are air dried into sheet form. Drying is performed at temperatures ranging from approximately 4 to 40°C for a period of time of about 7 to 48 hours.<!-- EPO <DP n="18"> --></p><p id="p0105" num="0105">In another embodiment, the integration layer is comprised of a co-polymer of polyethylene glycol and collagen that slowly absorbs liquid and slowly biodegrades. The adhesive nature of the co-polymer of polyethylene glycol and collagen may allow the system to be more efficiently placed into, and adhere to, a lesion or defect.</p><p id="p0106" num="0106">It is not intended that the integration layer recited in the present invention be limited to a co-polymer of polyethylene glycol and collagen. For example, in other embodiments, the integration layer or layers of the system may be comprised of collagen, fibrin, agarose, alginate, chitin, polylactic acid, polyglycolic acid, co-polymers polylactic and polyglycolic, and co-polymers of collagen and fibrin. In addition, the integration layer may further include materials to promote, stimulate, or inhibit growth and development of specific tissues and cells.</p><p id="p0107" num="0107">Examples of such materials include (but are not limited to): demineralized bone powder, growth and development factors such as bone morphogenic proteins; epidermal growth factors; enzymes that stimulate extra-cellular matrix alteration, such as chondroitinase ABC (<patcit id="pcit0013" dnum="US5916557A"><text>U.S. Patent No. 5,916,557</text></patcit>); and pro-angiogenic factors such as vascular endothelial cell growth factor (VEGF).</p><p id="p0108" num="0108">In embodiments of the present invention designed to promote vascularization, the integration layer of the present invention may contain anti-thrombogenic factor such as heparin, or highly negatively charged artificial materials such as styrene-ethylene or butylene-ethylene co-polymers that produce an anti-thrombogenic effect.</p><p id="p0109" num="0109">In another embodiment of the present invention designed to promote the formation of bone tissue (e.g. wherein osteoblasts are seeded in the support matrix) the integration layer may contain osteogenic factors and/or demineralized bone powder to stimulate the subchondral tissue <i>in situ.</i></p><heading id="h0012"><b>4. The Protective Layer</b></heading><p id="p0110" num="0110">The present invention also contemplates a support matrix, seeded with cells, further comprising a protective layer. The protective layer encapsulates the outer surface of a cell seeded support matrix. The protective layer insulates a cell-seeded support matrix from the mechanical and physiological trauma that, in some applications, is associated with the implantation of a cell seeded matrix into a host; while simultaneously allowing nutrients to move into said cell seeded matrix. In one embodiment, the protective layer is applied to the cell-seeded matrix before and / or after said matrix is removed from a tissue processor.<!-- EPO <DP n="19"> --></p><p id="p0111" num="0111">In a preferred embodiment, the protective layer comprises a proprietary solution, designated CT3, that is manufactured by Cohesion Technologies of Palto Alto, CA that is applied over the surface of a chondrocyte seeded matrix that has been removed after a given culture period in a tissue processor. In one embodiment, a surgeon applies this aerosolized CT3 to subchondral bone <i>in situ.</i> In placing the cellular support layer, a surgeon places the polymer material in the lesion and, without waiting for it to fully polymerize, places the neo-cartilage into position. In this way, the layer facing subchondral bone seals-off the subchondral bone and holds the cellular support layer (e.g. neo-cartilage) in place. The outer protective layer comprising said polymer is then applied in a form that rapidly polymerizes, and is applied in such a manner as to keep it below the articulating surface of the joint to prevent it from being displaced by friction.</p><p id="p0112" num="0112">In one embodiment, once the system is delivered or implanted into the defect or target lesion, the protective layer shields the new tissue from forces or processes directed towards it from the functional surface, thereby, facilitating the integration of the cellular support with the native tissue surrounding the lesion. For example, when used to protect implanted neo-cartilage, this protective layer can substitute for other types of protective surgical interventions rendering unnecessary the need for the removal of a thin layer of the patient's periosteum from a canalicular bone, and its subsequent securing in place over the system to contain the neo-cartilage.</p><p id="p0113" num="0113">In a system for producing neo-cartilage, it is further desirable for the protective layer to be positively charged or neutrally charged so as to chemically contain the natural matrix produced by the neo-cartilage as it develops and produces negatively charged components such as chondroitin sulfate and other glycosaminoglycans.</p><p id="p0114" num="0114">The protective layer of the system may take different forms. Utilization of one form over the other depends on the nature of the lesion and the lesion site to which the neo-tissue is to be delivered, returned, or implanted. In one embodiment the present invention contemplates a lesion or portion of a lesion, <i>in situ,</i> with said protective layer to create a lining and subsequently contacting a support matrix seeded with cells with said lining.</p><p id="p0115" num="0115">It is not intended that the present invention be limited to a multi-layered system comprising a protective layer made-up of any specific material. For example, in one embodiment, the protective layer comprises an adhesive sealant that is applied by the physician or surgeon after placing the integration layer and cellular support layer into the lesion, and is, therefore, not attached to the system at the time of initial seeding of cells. In order to form an effective seal, it is desirable for the adhesive sealant to be sprayed or applied<!-- EPO <DP n="20"> --> with an implement such as a large bore syringe such that the adhesive sealant may be easily manipulated by the practitioner prior to the polymerization (or setting) of the co-polymer.</p><p id="p0116" num="0116">It is further desirable that this material (<i>i.e</i>. sealant) be able to resist 0.01 - 15.00 MPa of stress. The material used for this application should be a biologically sound polymer that will eventually biodegrade in the body. An example of a material that is preferred is a copolymer (or construct) of polyethylene glycol and collagen. Indeed, for embodiments of the present invention wherein chondrocytes are seeded into a collagen matrix, collagen-based sealants are preferred. Some of the advantages of using such a co-polymer (or construct) in the protective layer include that said co-polymer is effective, safe, strong and durable, and that it may also be used by the physician as a surgical sealant after the delivery of the multi-layered system or matrix (and the corresponding cells or neo-tissue) into the target lesion.</p><p id="p0117" num="0117">In another embodiment, the outer/protective layer comprises a protective layer of a sealant (<i>i.e</i>. material) sprayed on the surface of the multi-layered system prior to culturing said system, and is then reinforced with more of the same material once it is placed in the lesion.</p><p id="p0118" num="0118">In another embodiment, any of the rapid gelling biocompatible polymer compositions described in <patcit id="pcit0014" dnum="US20010055615A"><text>U.S. Patent Application Serial No. 20010055615</text></patcit> (corresponding to Serial No. <patcit id="pcit0015" dnum="US09293708B"><text>09/293,708) to Wallace (Published December 27, 2001</text></patcit>) may be used as the protective layer in the present invention.</p><p id="p0119" num="0119">In yet another embodiment, the protective layer comprises a rigid, but flexible, material that can be applied by wedging it into a lesion site, effectively sealing-off the lesion and further fulfilling the protective function. Said embodiment may be referred to as a wedging protective layer. Examples of materials suitable for use in this embodiment include, but are not limited to, forms of polylactate or polylactic-polyglycolic acid co-polymer, and a non-woven condensed structure of N-glucosamine of varying degrees of acetylation. The present invention contemplates the use of such materials whether used individually or in combination. Moreover, the present invention contemplates further embodiments in which the adhesive sealant (referred to above) may also be used in conjunction with said wedging protective layer as an extra sealant around the periphery of the inserted system.</p><heading id="h0013"><b>III. TISSUE CULTURE DEVICES AND TISSUE PROCESSORS</b></heading><heading id="h0014"><b>1. Standard Incubators</b></heading><p id="p0120" num="0120">The methods of the present invention employ a variety of tissue culture devices. Standard tissue culture incubators and incubation environments are used to expand (or<!-- EPO <DP n="21"> --> multiply) cells harvested from tissues or organs. In a preferred embodiment, this expansion of cells is associated with the removal of dead cells and cellular debris (e.g. residual native extracellular matrix). That is to say, standard tissue culture techniques may be used to select out and multiply a desired population(s) of cells. These expanded cells may then be incorporated into the three dimensional cellular support matrices recited in the present invention. In a preferred embodiment, for example, chondrocytes harvested from articular cartilage are expanded in culture. These expanded chondrocytes are then seeded into the cellular support matrix to form a seeded matrix. This seeded matrix may then be placed into a tissue processor.</p><heading id="h0015"><b>2. Tissue Processors</b></heading><p id="p0121" num="0121">A tissue processor has the capacity to regulate / modify tissue culture conditions including the application of constant or cyclic hydrostatic pressure, the recirculation of media, and the regulation of oxygen concentration. In a preferred embodiment said tissue processor is the Tissue Engineering Support System (TESS) described in published <patcit id="pcit0016" dnum="US20010021529A"><text>U.S. patent application 20010021529</text></patcit> (corresponding to <patcit id="pcit0017" dnum="US796422A"><text>U.S. Patent Application Serial No. 09/796,422</text></patcit>) assigned to Takagi Industrial Co. Ltd.</p><p id="p0122" num="0122">The TESS processor provides an apparatus for cultivating cells or tissue comprising: a culture unit having a culture chamber containing cells or tissue and culture medium; a pressure application means for applying pressure to the cells or tissue in the culture chamber; and a culture medium supply means for the continuous or intermittent delivery supply of culture medium to the culture unit. (<i>See</i> <figref idrefs="f0001">Figure 1</figref> and corresponding text of <patcit id="pcit0018" dnum="US796422A"><text>U.S. Patent Application Serial No. 09/796,422</text></patcit>). The TESS processor may also comprise a control means (<i>e.g</i>. pressure relief valve) for controlling the pressure application means or culture medium supply means. Generally, the pressure applied to the cells or tissue is set depending on the type of cells or tissue to be grown. The TESS processor further comprise a means capable of absorbing gases such as nitrogen, carbon dioxide, and oxygen. Also, the TESS processor further comprises a hermetically sealed space including a heating means and a humidifying means.</p><heading id="h0016"><b>3. Applications Of Tissue Processors</b></heading><p id="p0123" num="0123">Certain cells are extremely difficult to grow in three-dimensional (3-D) culture such that they may form a neo-tissue (e.g. neo-cartilage). The TESS processor not only facilitates the growth and culture of these difficult to grow cells but it allows a mixed culture of cells to<!-- EPO <DP n="22"> --> be grown together. These mixed populations of cells may be cultured in the TESS under conditions such that they self-organize into a tissue construct that approaches the histological organization of an <i>in situ</i> organ. While it is not intended that the present invention be limited by any specific tissue culture mechanism or protocol, the TESS perfuses medium under pressure, thereby, facilitating the delivery of oxygen and nutrients to the interior of cell seeded 3-D matrices.</p><p id="p0124" num="0124">Neo-tissues could be composed of healthy human or cancerous cells. Cancerous cells could be used as a model system for screening anticancer and allow investigator to develop, in vitro, the optimum drug regimen in advance of clinical trials</p><p id="p0125" num="0125">For example, a 3-D neotissue comprised of epithelium-derived secretory cells and mesoderm-derived stromal cells could approximate the morphology of <i>in situ</i> prostate tissue. Such a "prostate like" neo-tissue could allow an investigator to screen, as a prostate tumor repression drug, the many analogues of vitamin D.</p><p id="p0126" num="0126">Furthermore, these 3-D cultures could be comprised of a cancerous cells (from a metastasized tumor in one organ) and "normal" cells that are the target for the metastasizes of said cancerous cells, thereby, facilitating the study metastatic interactions. Such systems would be especially important in cases where cancer mortality results not from a primary cancer of epithelial secretory cells (<i>e.g</i>. in prostate or breast cancer), but from the transformation of bone by interaction with migrating cells from the primary cancer site. Such a 3-D culture would be valuable in evaluating the combinatory drugs regimens indicated for prostate metastasis (e.g. androgen repressors/chemotherapeutic agents such as carboplatin).</p><heading id="h0017"><b>IV. OVERVIEW OF THE FORMATION OF NEO-TISSUES</b></heading><p id="p0127" num="0127">The present invention provides methods for the formation of neo-tissue using the components of the multi-layered system described above. More specifically these components are combined and reacted under conditions such that a viable three dimensional neo-tissue is produced. The combination and reaction conditions for these components may be varied according type of neo-tissue produced and the intended application for this same neo tissue. In a preferred embodiment, however, neo-cartilage is produced according to the following scheme.</p><heading id="h0018"><b>1. Isolation Of Chondrocytes From Source Tissue</b></heading><p id="p0128" num="0128">Chondrocytes were enzymatically isolated from cartilage harvested under sterile conditions from the hind limbs of 6-month old swine. The femur was detached from the tibia<!-- EPO <DP n="23"> --> and the trochlea head exposed. Strips of cartilage were removed from the trochlea using a surgical blade. The cartilage was minced, digested in a 0.15% collagenase type I solution in DMEM: Nutrient Mixture F-12 (DMEM/F-12) 1:1 mixture with 1% penicillin-streptomycin (P/S) and gently rotated for 18 hours at 37°C. Chondrocytes were collected and rinsed twice with PBS by centrifugation at 3000 rpm for 5 min. Chondrocytes were re-suspended in DMBM/F-12 supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% P/S.</p><heading id="h0019"><b>2. Seeding Cells In The TESS Matrix</b></heading><p id="p0129" num="0129">Isolated chondrocytes were incubated for a period of five days at 37°C in a standard incubator. Cells were then collected by trypsinization. A cell suspension of 150,000 cells in 18 ul of VITROGEN solution was seeded per matrix (said matrix having an approximate volume of 19ul) with nine matrices per group. It is not intended that the present invention be limited to specific cellular support matrix size or shape or number of cells. Indeed, in one embodiment of the present invention, the seeded matrix may be scaled-up to an increased volume (wherein approximately 1ul of the above described cell suspension is seeded in 1ul of matrix). The control group matrices were incubated in a 37°C incubator and the test group was incubated in the TESS. (See, Example 1 and Table 1).</p><p id="p0130" num="0130">In another experimental example, isolated chondrocytes were incubated for a period of five days at 37°C in a standard incubator. Cells were then collected by trypsinization. A cell suspension of 300,000 cells in 18 ul of VITROGEN solution was seeded per matrix (said matrix having an approximate volume of 19ul) with eight matrices per group. It is not intended that the present invention be limited to specific cell numbers or cellular support matrix size or shape. Indeed, in one embodiment of the present invention, the seeded matrix may be scaled-up to an increased volume (wherein approximately 1ul of the above described cell suspension is seeded in 1ul of matrix). The control group matrices were incubated in a 37°C incubator and the test group was incubated in the TESS. (See, Example 2 and Table 2).</p><heading id="h0020"><b>3. Biochemistry (DMB Assay)</b></heading><p id="p0131" num="0131">At the end of the culture six matrices from each group were used in the biochemistry assay. Briefly, the matrices were transferred to microcentrifuge tubes and digested in 300 µl of papain (125 µg/ml in 0.1 M sodium phosphate, 5 mM Disodium EDTA, and 5 mM L-cysteine-HCL) for 18 hours at 60°C. GAG production in the matrices was measured using a<!-- EPO <DP n="24"> --> modified dimethylene blue (DMB) miocroassay with shark chondroitin sulfate as a control (Reference: <nplcit id="ncit0002" npl-type="s"><text>Connective Tissue Research, 1982, vol.9, pp 247-248</text></nplcit>)</p><heading id="h0021"><b>4. Histology</b></heading><p id="p0132" num="0132">The remaining matrices from each group were fixed in 4% paraformaldehyde. The matrices were processed and embedded in paraffin. 10 µm sections were cut on a microtome and stained with Safranin-O (Saf O).</p><heading id="h0022"><b>V. PREFERRED PROTOCOLS FOR NEO-TISSUE GROWTH</b></heading><p id="p0133" num="0133">The present invention contemplates protocols for the growth (<i>i.e. in vivo, ex vivo,</i> and <i>in vitro</i>) of neo-tissues, using the component of the multi-layered system described in the instant application. In preferred embodiments, the TESS processor is used to deliver constant or cyclic hydrostatic pressure to the cell-seeded matrix. In this preferred embodiment, these cell-seeded matricies are maintained in resting phase (in one example in a standard incubator or TESS processor maintained at 37°C at atmospheric pressure) subsequent to constant or cyclic hydrostatic pressure exposure.</p><heading id="h0023"><b>1. Production Of Neo-cartilage</b></heading><p id="p0134" num="0134">In a preferred embodiment, autologous pig chondrocytes are seeded into the cellular support matrix and incubated under cyclic hydrostatic pressure at 37°C and 5% CO<sub>2</sub>. In this preferred embodiment, said cyclic hydrostatic pressure is approximately 3.0 MPa of pressure at 0.5 Hz. In this preferred embodiment the duration of said cyclic pressure is approximately 6 days followed by a resting phase of 12 days in an incubator maintained at 37°C at atmospheric pressure. At the end of this resting phase, the matrices were harvested for biochemical and histological analysis as described in Example 1 and Example 2.</p><heading id="h0024"><b>2. Alternative Protocol</b></heading><p id="p0135" num="0135">In another embodiment, the present invention contemplates an algorithm for the growth (<i>i.e. in vivo, ex vivo,</i> and <i>in vitro</i>) of cells, using the components of the present invention, involving the application of hydrostatic pressure to isolated <i>in situ</i> cartilage (or chondrocytes adhered to a matrix) and subjected to the regimen comprising the cyclic application of hydrostatic pressure for about 1-8 hours followed by about 16-23 hours of recovery period.<!-- EPO <DP n="25"> --></p><heading id="h0025"><b>3. Reduced Oxygen Concentration</b></heading><p id="p0136" num="0136">In an alternative embodiment the chondrocytes-seeded cellular support matrix described above may be cultured under reduced O<sub>2</sub> concentration (<i>i</i>.<i>e</i>. less than 20% saturation) during formation of neo-cartilage in the TESS processor. While it is not intended that the present invention be limited to any specific mechanism, the reduced oxygen concentration of cartilage, observed <i>in vivo</i>, may be due to its (normal) lack of vascularization which produces a lower (as compared to the adjacent tissues) oxygen partial pressure. In one embodiment, neo-tissues are cultured under oxygen concentration between approximately 0% and approximately 19% saturation. In another embodiment, said oxygen concentration is approximately 2% saturation.</p><heading id="h0026"><b>VI. MEDICAL APPLICATIONS</b></heading><p id="p0137" num="0137">The compositions and methods of the present invention are suitable for use in a variety of medical applications. In one embodiment, the heat-cured, cell-seeded matrix described in the present invention may be implanted <i>in vivo</i> to repair damaged cells or tissue. In another example, the heat cured cell seeded matrix of the present invention may replace or augment existing tissue or to join together biological tissues or structures as described below.</p><heading id="h0027"><b>1. Tissue Repair Applications</b></heading><p id="p0138" num="0138">It is not intended that the use of the compositions and methods of the present invention be limited to the repair, replacement, reconstructed or augmentation of any specific tissue (or cell) type. For example, in one embodiment, damaged cartilaginous tissue is repaired, replaced, reconstructed or augmented. In another embodiment, tissue defects left by tumor, trauma, infection, or congenital malformation (involving various tissue or cell types) are repaired, replaced, reconstructed or augmented.</p><heading id="h0028"><b>A. Cartilage Repair</b></heading><p id="p0139" num="0139">While the present invention provides composition and methods for the repair of full thickness cartilaginous defects, they may also be directed to the repair of partial thickness defects. Further, the systems and methods of the present invention may be combined with techniques for forming templates of defect areas so that customized formed neo-tissues may be produced that are dimensionally adapted and tailored for a particular patient's defect. In addition, the systems and methods of the present invention may be used to create entire cartilaginous structures such as menisci, or may be used to create materials for partial or total<!-- EPO <DP n="26"> --> replacement of an articular surface. In other embodiments, cartilaginous neo-tissues (<i>i</i>.<i>e</i>. neo-cartilage) according to the present invention may be available for combining with alloplastic materials to form artificial joints. In one embodiment, the cartilaginous neo-tissues (<i>i.e</i>. neo-cartilage) described in the present invention will repair and / or replace tendons and ligaments. In a specific embodiment said ligament is the anterior cruciate ligament (ACL). In another embodiment, the cartilaginous neo-tissues (<i>i.e.</i> neo-cartilage) described in the present invention will repair and / or replace vertebral disks.</p><p id="p0140" num="0140">The compositions and methods of the present invention may be adaptable to formation of neo-tissue constructs combining, for example, formed cartilage and formed bone to be used for replacement of an entire articular surface including sub-chondral bone, or will be used for replacement of a cartilage covered small bone such as may be found in the wrist. Whether used for Forming cartilaginous neo-tissue, or for forming neo-tissue constructs, these compositions may be fashioned into implantable structures for total joint replacement, and for hemi-joint replacement in small joints such as those in the hand or the temporomandibular joint.</p><p id="p0141" num="0141">In another embodiment, these systems and methods may be used for creating an implantable, full-thickness, cartilaginous neo-tissue to be placed in a large weight bearing joint such as the knee. Arthroscopic procedures may be advantageously utilized in harvesting native chondrocytes to be incorporated in a neo-tissue formed by these compositions and methods.</p><p id="p0142" num="0142">In one embodiment of the present invention, a first arthroscopic procedure will be employed to evaluate the extent of the potential cartilaginous defect and to harvest native chondrocytes for subsequent culturing and delivery into the cellular support matrix described in the present invention. Based on a template formed at the time of this first arthroscopic procedure, or based on measurements made during the procedure, a dimensional model will be formed of the anticipated defect and the neo-tissue will be formed to conform in size and shape to this model</p><p id="p0143" num="0143">A second arthroscopic procedure will be carried out to debride a damaged area of the <i>in situ</i> native cartilage and to replace the damaged area with the neo-cartilage prepared according to the present invention.</p><p id="p0144" num="0144">Other adaptations of conventional surgical techniques will be employed at other anatomic sites for harvesting native cartilage cells, for debriding damaged cartilage tissue, for creating a defect within the host articular surface (<i>e.g</i>. including a complete excision of a<!-- EPO <DP n="27"> --> joint surface or a partial excision of a joint surface), for implanting neo-tissue into the host defect and for retaining the neo-tissue in that site.</p><heading id="h0029"><b>B. Tissue Defect Repair</b></heading><p id="p0145" num="0145">Defects left by tumor, trauma, infection, or congenital malformation, are well-known in the medical and surgical arts. Reconstruction of such defects may require full-thickness tissue replacement, or may require replacement of tissue constructs. For example, in one embodiment, an excision taken from the lower eyelid (<i>e.g</i>. in the case of a basal cell carcinoma) may need to be reconstructed by an extensive flap procedure that "employs" adjacent tissues or tissues from the upper lid. Alternatively, grafting procedures using the other lids or nasal septum as donor sites may be employed (despite the fact that there may be donor site problems, and that some local tissue rearrangement will be required at the reconstructed area).</p><p id="p0146" num="0146">The present invention may be adapted to repair these defects. For example, a neo-tissue construct providing both neo-cartilage and a covering layer (conjunctival or epidermal) will be positioned in such a defect to simplify the reconstructed task. Alternatively, a neo-tissue comprising all three layers of eyelid tissue could omit the need for any substantial local tissue rearrangement. A neo-tissue comprising neo-cartilage would obviate the need for harvesting a cartilage graft from elsewhere with the consequent donor site risks.</p><p id="p0147" num="0147">In another embodiment, a nasal-septal deformation defect will be repaired using neo-cartilage. Repair of persistent fistulas after cleft palate procedures may also be amenable to treatment with the neo-cartilage described in the present invention. These fistulas left from cleft palate repairs may require reconstruction using a tissue construct with two outer mucosal layers covering an inner bony layer.</p><p id="p0148" num="0148">In another embodiment, the neo-tissues described in the present invention will also be adapted to difficult reconstructive problems. Using the compositions and methods of the present invention oral mucosa could be produced in significant quantities to fill or surface intraoral defects with a specialized tissue having functional characteristics appropriate for the intraoral location. Reconstruction of other specialized areas such as nail beds and articular cartilage for large and small joints may also be undertaken using the compositions and methods of the present invention. The present invention may also provide reconstructive solutions to damaged temporomandibular joint or may be applied to repairing degenerative diseases such as rheumatoid arthritis.<!-- EPO <DP n="28"> --></p><heading id="h0030"><b>C. Ligament and Tendon</b></heading><p id="p0149" num="0149">The compositions and methods of the present invention will be adapted to the production of tendon and ligaments <i>in vitro.</i> In one embodiment, this will be promoted by the stretching of ligament and tendon progenitor cells, over a scaffold, <i>ex vivo</i> during the exogenous development of ligament or tendon. The ligaments contemplated by the present invention will be derived from ligament progenitor cells, mesenchymal stem cells, or fibroblasts, especially fibroblasts derived from the sheath cells surrounding ligament and tendon, or fibroblast or tenocytes derived from the ligament or tendon themselves. Autologous ligaments and tendons may be used to replace damaged ligaments and tendons in a patient's own body without fear of immune response or other adverse response.</p><p id="p0150" num="0150">The stretching scaffold, referenced above, may be considered another layer in the multiplayer composition described in the present invention. This scaffold will allow the progenitor cells to be stretched <i>ex vivo</i> (for example in a modified TESS processor) so as to apply a physical stimulus which causes them to produce proteins and matrix components which are consistent with true neo-ligaments or neo-tendons.</p><p id="p0151" num="0151">In one embodiment, the stretching scaffolding will consist of a fibrous material that can resist tensile stresses that fall within the range of tensile stresses to which cartilage and ligament are normally subjected in the course of lifetime. More specifically, the fibrous material may resist a range of tensile stresses which are necessary to induce said cells to begin producing the normal gene products in the correct ratio that differentiate ligament and tendon from other tissues or organs, and that allow these gene products to take on the orientation and physical condition, such that a healthy and morphologically sound ligament or tendon may develop on such scaffolding. Also, the fibrous material should have a degree of elasticity which can accommodate the amount of progenitor cell stretching required to induce said cells to form neo-ligament or neo-tendon.</p><p id="p0152" num="0152">The ligament and tendon developed upon such scaffolding will acquire a tensile strength, an elasticity and a structure to support bone and muscle <i>in vivo,</i> which is equivalent to the tensile strength and structure of ligament and tendon developed within the body during the normal course of growth and differentiation. The scaffold is also designed so that once the neo-ligament or neo-tendon is sufficiently functional, the scaffolding will reintroduce the ligament or tendon into the lesion and support until it integrates in the body. In one embodiment the scaffolding will degrade after implantation.</p><p id="p0153" num="0153">In one embodiment, the cells placed on the scaffolding will be chosen from cells at a stage in their developmental life such that (when on placed on the scaffolding and subjected<!-- EPO <DP n="29"> --> to the physical and chemical conditions of a 3-D tissue culture apparatus designed to induce differentiation of cartilage and ligament) these cells will produce substantially all of the gene products elaborated by morphologically-sound ligaments or tendons.</p><p id="p0154" num="0154">In one embodiment, the scaffolding is selected from variety of materials, including but not limited to, polyesters (including polyalkynoates), polyglycolates, polylactates, biodegradable suture materials. Other materials may also be suitable so long as these materials can safely degrade within the body, and so long as the products of the degradation do not interfere with the normal metabolic function of the cartilage and ligament or the surrounding tissue.</p><p id="p0155" num="0155">The physical structure of the scaffold need be consistent with its intended function (e.g. the uniform application of tensile stress at the cellular (micrometer) level). These stresses are very mild compared with the stresses place upon the mature cartilage or ligament. It is also important that the fibrous structure resists rupturing at the required tensile strengths. In one embodiment, fibers of 1-10 micrometer diameter will be woven into a variety of weave patterns including, but not limited to a solid weave, a hollow centered weave (such as the Chinese puzzle weave) such that the application of tensile stress to the ends of the scaffold will produce a uniform stretching of the surface of the scaffold. To produce a ligament with its own bone anchoring points it would be possible to incorporate at the polar ends of the scaffold such substances as demineralized bone powder, which under the correct physical stimulus would be induced to form bone to be incorporated into existing bone when placed <i>in situ</i> in the body.</p><heading id="h0031"><b>D. Other Applications</b></heading><p id="p0156" num="0156">The compositions and methods of the present invention may also be used as a model for elucidating the mechanism of certain diseases. For example, in one embodiment, the multi-layered systems of the present invention may also be used as models for the study of physiologic or pathologic conditions <i>in vitro.</i> For example, in one embodiment of the invention, the system may be used as a model for the blood-brain barrier.</p><p id="p0157" num="0157">Alternatively, the compositions and methods of the present invention may be used for studying the pharmacokinetics of various drugs and growth factors. For example, the neo-tissues<!-- EPO <DP n="30"> --> described in the present invention may also be used for the <i>in vitro</i> screening of cytotoxic compounds, allergens, growth and regulatory factors, pharmaceutical compounds. To this end, the neo-tissue may be maintained <i>in vitro</i> and exposed to the compound to be tested. For example, the activity of a cytotoxic compound can be measured by its ability to damage or kill cells in culture. This may be readily assessed by known vital staining techniques.</p><p id="p0158" num="0158">The effect of growth or regulatory factors may be assessed by analyzing the cellular content of a neo-tissue, for example, by total cell counts and / or differential cell counts. This may be accomplished using standard cytological and/or histological techniques including the use of immunocytochemical techniques employing antibodies that define type-specific cellular antigens. The effect of various drugs on normal cells cultured in the three-dimensional system may be assessed. For example, drugs that increase red blood cell formation can be tested on three-dimensional bone marrow cultures. Drugs that affect cholesterol metabolism, by lowering cholesterol production for example, could be tested on the three-dimensional liver system. Three-dimensional cultures of tumor cells may be used as model systems to test, for example, the efficacy of anti-tumor agents.</p><p id="p0159" num="0159">The compositions and methods of the present invention may also be used to aid in the diagnosis and treatment of malignancies and diseases. For example, a biopsy of any tissue (e.g. bone marrow, skin, liver, etc.) can be taken from a patient suspected of having a malignancy. If the biopsy cells are cultured in system of the invention, malignant cells may be clonally expanded during proliferation of said culture, thereby increasing the chances of detecting a malignancy and, therefore, increasing the accuracy of the diagnosis and timeliness of treatment. Such an application of the present invention may be especially useful in diseases such as AIDS where the infected population of cells is depleted <i>in vivo.</i> Moreover, in such a case, the patient's culture could be used <i>in vitro</i> to screen compounds (e.g. cytotoxic compounds or pharmaceuticals) in order to identify those that are most efficacious (<i>i.e.</i> those that kill the malignant or diseased cells, yet spare the normal cells). These agents could then be used to therapeutically treat the patient.</p><heading id="h0032"><b>VII. ALTERNATIVE EMBODIMENTS</b></heading><p id="p0160" num="0160">While certain embodiments of the multi-layered system for producing neo-tissues or neo-tissue constructs comprise a three-layer construction, the present invention also contemplates multi-layered systems comprising more than three layers.<!-- EPO <DP n="31"> --></p><p id="p0161" num="0161">For example, in producing a neo-tissue or neo-tissue construct, the layers of the multi-layered system may be arranged to include: a bottom, tissue attachment layer; a second layer supporting a biologic matrix, wherein resides a first type of tissue cell; a third, integrating layer deployed atop the second layer to integrate the second layer with an additional layer of biologic matrix, wherein resides a second type of tissue cell; and a top, protective layer arranged on top of the additional layer of biologic matrix. Such an arrangement could provide for a tissue construct including a layer of cartilage protected by a layer of mucosa. Preferably, the integrating layer would be formed of a material that would enhance the normal attachment of the cartilage layer and the mucosal layer so that their unitary behavior under physiologic conditions would replicate the behavior of the native tissue.</p><p id="p0162" num="0162">More complex structures with multiple cellular support matrices seeded with cells from at least two tissue types are also contemplated, with integrating layers positioned between each matrix. For example, a tissue construct of the nasal septum could be fabricated (according to these principles) with an outer mucosal layer, an inner cartilaginous layer, and a second outer mucosal layer.</p><p id="p0163" num="0163">In another embodiment, a neo-tissue construct according to the present invention may be produced that includes the three layers of the nasal septum.</p><p id="p0164" num="0164">In other embodiments, the neo-tissues described by the present invention may be fashioned into a variety of shapes. For example, tubular structures such as blood vessels, ducts or other specialized conduits (e.g. ureter, ureter, esophagus, etc.) may be formed by sculpting a neo-tissue around a mandrel or other tube forming shape.</p><p id="p0165" num="0165">In other embodiments the compositions and methods of the present invention could be used to create luminal, tubular or cylindrical structures such as, for example, a multi-layered blood vessel.</p><p id="p0166" num="0166">In another embodiment, the compositions and methods of the present invention may be used to produce a replica of a tendon or a ligament (<i>i.e</i>. neo-tendon or neo-ligament). The multi-layered system of the present invention may be formed within an external guiding tube to produce a structure that functionally replicates a tendon. To fashion a neo-ligament a seeded cellular support matrix may be inserted into an external guiding tube that would act as a shaping template for the neo-ligament. In another embodiment, a slowly degrading mandrel may be employed using a material like polyglycolic lactic acid (PGLA).<!-- EPO <DP n="32"> --></p><p id="p0167" num="0167">In a further embodiment, the multi-layered system of the present invention is fashioned into an <i>in vitro</i> tissue construct to screen cytotoxic and pharmaceutical compounds, and to assess biological responses to cytokines and growth/regulatory factors.<!-- EPO <DP n="33"> --></p><heading id="h0033"><b>EXPERIMENTAL</b></heading><p id="p0168" num="0168">The following examples serve to illustrate preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.</p><heading id="h0034"><b>Example 1</b></heading><p id="p0169" num="0169">This example provides one instance in which tissues were formed <i>in vitro</i> in one embodiment of the present invention. Briefly, swine articular chondrocytes (sACs) were enzymatically isolated from cartilage with type I collagenase. The cells were suspended in collagen (VITROGEN) as described above and wicked into the honeycombed sponge element of the cellular support matrix (e.g. the TESS matrix). The cells in their 3-D support (<i>i.e.</i> the TESS matrix) were incubated at 37°C, 5% CO<sub>2</sub> and 20% O<sub>2</sub>. After 24 hours, some of these cell matrices (<i>i.e</i>. cellular support layers comprising the test group) were transferred to the TESS™ processor and incubated at 3.0 MPa cyclic hydrostatic pressure as described above for 6 days followed by a 12 day resting phase.</p><p id="p0170" num="0170">The control group comprised of chondrocyte-seeded TESS matrices incubated for 18 days, at 37°C, 5% CO<sub>2</sub> and 20% O<sub>2</sub> and at atmospheric pressure.</p><p id="p0171" num="0171">At the end of the culture period, the matrices were harvested for biochemical and histological analysis as noted in Table 1. For biochemical analysis, glycosaminoglycan (GAG) production was measured using a modified dimethymethylene blue (DMB) microassay. <figref idrefs="f0001">Figure 1</figref>, described in the "Description Of The Drawings" of the instant specification, represents, in graph form, the data set out in Table 1. For histological analysis, formation of neo-tissue was measured by Safranin-O staining. The histology of the control group is illustrated in <figref idrefs="f0002">Fig. 2A</figref>. The histology of the test group is projected in <figref idrefs="f0003">Fig. 2B</figref>.<!-- EPO <DP n="34"> -->
<tables id="tabl0001" num="0001"><table frame="all"><title><b>Table 1</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="33mm"/><colspec colnum="3" colname="col3" colwidth="35mm"/><colspec colnum="4" colname="col4" colwidth="32mm"/><colspec colnum="5" colname="col5" colwidth="33mm"/><thead><row><entry morerows="1" align="center" valign="top">Group (n=8 matricies per group)</entry><entry namest="col2" nameend="col3" align="center" valign="top">Pressure Conditions</entry><entry morerows="1" align="center" valign="top">Total days In culture</entry><entry morerows="1" align="center" valign="top">GAG Production (ng/ml) (mean +/- SD) (n = 6 matricies)</entry></row><row><entry align="center" valign="top">In TESS (3 MPa Cyclic Pressure,@0.5 Hz)</entry><entry align="center" valign="top">In Incubator (Atmospheric Pressure)</entry></row></thead><tbody><row><entry align="center">Control</entry><entry align="center">-</entry><entry align="center">18 days</entry><entry align="center">18</entry><entry align="center">4.71±0.71</entry></row><row><entry align="center">Test</entry><entry align="center">6 days</entry><entry align="center">12 days</entry><entry align="center">18</entry><entry align="center">14.11±1.10</entry></row></tbody></tgroup><tgroup cols="5" rowsep="0"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="33mm"/><colspec colnum="3" colname="col3" colwidth="35mm"/><colspec colnum="4" colname="col4" colwidth="32mm"/><colspec colnum="5" colname="col5" colwidth="33mm"/><tbody><row><entry namest="col1" nameend="col5" align="justify">NOTE: 1) All cultures were incubated at 37°C, 5% CO2 and 20% 02.<br/>
2) In TESS culture, media flow rate was 0.05 ml/min.<br/>
3) Two matricies from each group were harvested for histological analysis.</entry></row></tbody></tgroup></table></tables></p><heading id="h0035"><b>Example 2</b></heading><p id="p0172" num="0172">This example provides another instance in which tissues were formed <i>in vitro</i> in another embodiment of the present invention. Swine articular chondrocytes (sACs) were enzymatically isolated from cartilage with type I collagenase. The cells were suspended in collagen (VITROGEN) as described above (e.g. 300,000 cells in 18ul of VITROGEN) and were wicked into the honeycomb sponge element of the cellular support matrix (i.e. the TESS matrix), wherein each matrix had a volume of approximately 19ul.</p><p id="p0173" num="0173">The cells in their cellular support matrix were incubated at 37°C, 5% CO<sub>2</sub> and 20% O<sub>2</sub>. After 24 hours, some of these cell matrices (the test group) were transferred to the TESS<sup>™</sup> processor and incubated at 3.0 MPa cyclic hydrostatic pressure as described above for 6 days followed by incubation for 12 days at atmospheric pressure at 37°C, 5% CO<sub>2</sub> and 20% 0<sub>2</sub>.</p><p id="p0174" num="0174">The remaining cell matrices comprising the control group were incubated at atmospheric pressure for 18 days at 37°C, 5% CO<sub>2</sub> and 20% 0<sub>2</sub>.</p><p id="p0175" num="0175">At the end of the culture period, the matrices were harvested for biochemical and histological analysis as noted in Table 2. For biochemical analysis, glycosaminoglycan (GAG) production was measured using a modified dimethymethylene blue (DMB) microassay. <figref idrefs="f0006">Figure 4</figref>, described in the "Description Of The Drawings" of the instant<!-- EPO <DP n="35"> --> specification, represents, in graph form, the data set out in Table 2. For histological analysis, formation of neo-tissue was measured by Safranin-O staining. The histology of the control group is illustrated in <figref idrefs="f0004">Fig. 3A</figref>. The histology of the test group is projected in <figref idrefs="f0005">Fig. 3B</figref>.
<tables id="tabl0002" num="0002"><table frame="all"><title><b>Table 2</b></title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="33mm"/><colspec colnum="3" colname="col3" colwidth="34mm"/><colspec colnum="4" colname="col4" colwidth="32mm"/><colspec colnum="5" colname="col5" colwidth="33mm"/><thead><row><entry morerows="1" align="center" valign="top">Group (n = 8 matricies per group)</entry><entry namest="col2" nameend="col3" align="center" valign="top">Pressure Conditions</entry><entry morerows="1" align="center" valign="top">Total days In culture</entry><entry morerows="1" align="center" valign="top">GAG Production (ng/ml) (mean +/- SD) (n = 6 matricies)</entry></row><row><entry align="center" valign="top">In TESS (3 MPa Cyclic Pressure,@0.5 Hz)</entry><entry align="center" valign="top">In Incubator (Atmospheric Pressure)</entry></row></thead><tbody><row><entry align="center">Control</entry><entry align="center">-</entry><entry align="center">18 days</entry><entry align="center">18</entry><entry align="center">19.24±2.14</entry></row><row><entry align="center">Test</entry><entry align="center">6 days</entry><entry align="center">12 days</entry><entry align="center">18</entry><entry align="center">25.44±1.37</entry></row></tbody></tgroup><tgroup cols="5" rowsep="0"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="33mm"/><colspec colnum="3" colname="col3" colwidth="34mm"/><colspec colnum="4" colname="col4" colwidth="32mm"/><colspec colnum="5" colname="col5" colwidth="33mm"/><tbody><row><entry namest="col1" nameend="col5" align="justify">NOTE:1) All cultures were incubated at 37°C, 5% CO<sub>2</sub> and 20% 0<sub>2</sub>.<br/>
2) In TESS culture, media flow rate was 0.05 ml/min.<br/>
3) Two matricies from each group were harvested for histological analysis.</entry></row></tbody></tgroup></table></tables></p><p id="p0176" num="0176">From the above description and examples, it should be clear that the present invention provides compositions and methods for the preparation of tissues and tissue constructs.</p></description><claims mxw-id="PCLM56983367" lang="DE" load-source="patent-office"><!-- EPO <DP n="38"> --><claim id="c-de-01-0001" num="0001"><claim-text>Ein implantierbares mehrschichtiges Konstrukt, dessen Herstellungsverfahren die folgenden Schritte umfasst:
<claim-text>a) Bereitstellen einer implantierbaren mehrschichtigen Struktur, bestehend aus:
<claim-text>(i) einer Integrationsschicht,</claim-text>
<claim-text>(ii) einer zellulären Trägerschicht, die eine Schwammmatrix beinhaltet und mit der Integrationsschicht funktional verbunden ist,</claim-text></claim-text>
<claim-text>(b) Einbringen einer Lösung, die suspendierte Chondrozyten enthält, in besagte mehrschichtige Struktur, so dass ein besiedeltes Gerüst entsteht, und</claim-text>
<claim-text>(c) Kultivieren besagten besiedelten Gerüsts unter Bedingungen, die zyklischen hydrostatischen Druck mit einer anschließenden Ruhephase bei atmosphärischem Druck umfassen.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Das Konstrukt nach Anspruch 1, desweiteren beinhaltend:
<claim-text>(iii) eine Schutzschicht zur Abschirmung einer Außenfläche der zellulären Trägerschicht, wobei die Schutzschicht funktional mit der zellulären Trägerschicht und der Integrationsschicht verbunden ist.</claim-text><!-- EPO <DP n="39"> --></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Das Konstrukt nach Anspruch 1, wobei der zyklische hydrostatische Druck in einem Bereich von 0,01 bis 10 MPa bei 0,5 Hz liegt.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Das Konstrukt nach Anspruch 1, wobei es sich bei besagter Lösung um eine wässrige Kollagen Typ I Lösung handelt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Das Konstrukt nach Anspruch 1, wobei es sich bei besagter Lösung um eine Sol-Gel-Lösung handelt.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Das Konstrukt nach Anspruch 5, wobei besagtes Sol-Gel zumindest teilweise geliert ist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Das Konstrukt nach einem der vorangehenden Ansprüche, wobei besagte Chondrozyten in besagtem Gerüst im Wesentlichen immobilisiert sind.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Das Konstrukt nach Anspruch 1, wobei besagter Kultivierungsschritt zu einer Aktivierung der genannten Chondrozyten führt, um Genprodukte zu bilden, die mit einer extrazellulären Matrix assoziiert sind.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Das Konstrukt nach Anspruch 1, wobei besagter Kultivierungsschritt unter einem zyklischen hydrostatischen Druck im Bereich von 0,5 bis 5 MPa bei 0,5 Hz mit einer anschließenden 1 bis 60 Tage dauernden Ruhephase bei atmosphärischem Druck durchgeführt wird.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Das Konstrukt nach Anspruch 1, wobei besagter Kultivierungsschritt unter zyklischem hydrostatischen Druck fünf bis acht Tage lang durchgeführt wird.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Das Konstrukt nach Anspruch 1, wobei die Ruhephase 1 bis 60 Tage andauert.<!-- EPO <DP n="40"> --></claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Das Konstrukt nach Anspruch 1, wobei besagter Kultivierungsschritt unter einem zyklischen hydrostatischen Druck von 3 MPa bei 0,5 Hz mit einer anschließenden zwölftägigen Ruhephase durchgeführt wird.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Das Konstrukt nach Anspruch 1, wobei besagte Integrationsschicht ein Kopolymer aus Polyethylenglycol und Kollagen, Kollagen, Fibrin, Agarose, Alginat, Chitin, Polymilchsäure, Polyglycolsäure, ein Kopolymer aus Polymilchsäure und Polyglycolsäure oder ein Kopolymer aus Kollagen und Fibrin beinhaltet.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Das Konstrukt nach Anspruch 1, wobei besagte Schwammmatrix aus Kollagen Typ I hergestellt wird.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Das Konstrukt nach Anspruch 1, wobei das besagte besiedelte Gerüst bei reduzierter Sauerstoffkonzentration mit einer Sättigung unter 20 % kultiviert wird.</claim-text></claim></claims><claims mxw-id="PCLM56983368" lang="EN" load-source="patent-office"><!-- EPO <DP n="36"> --><claim id="c-en-01-0001" num="0001"><claim-text>An implantable multi-layered construct prepared by a process comprising the steps of:
<claim-text>(a) providing an implantable-multilayered structure comprising:
<claim-text>(i) an integration layer;</claim-text>
<claim-text>(ii) a cellular support layer comprising a sponge matrix and being operably linked to the integration layer;</claim-text></claim-text>
<claim-text>(b) introducing a solution comprising suspended chondrocytes into said multilayered structure to create a seeded device; and</claim-text>
<claim-text>(c) culturing said seeded device under conditions comprising cyclic hydrostatic pressure followed with a resting phase at atmospheric pressure.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The construct of claim 1, further comprising:
<claim-text>(iii) a protective layer insulating an outer surface of the cellular support layer, the protective layer being operably linked to the cellular support layer and the integration layer.</claim-text></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The construct of claim 1, wherein the cyclic hydrostatic pressure ranges from 0.01 to 10 MPa at 0.5Hz.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The construct of claim 1, wherein said solution is an aqueous Type I collagen solution.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The construct of claim 1, wherein said solution is a sol-gel.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The construct of claim 5, wherein said sol-gel is at least partially gelled.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The construct of any of the preceding claim, wherein said chondrocytes are substantially immobilized within said device.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The construct of claim 1, wherein said culturing step results in an<!-- EPO <DP n="37"> --> activation of said chondrocytes to elaborate gene products associated with an extracellular matrix.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The construct of claim 1, wherein said culturing step is performed under the cyclic hydrostatic pressure ranging from 0.5 to 5 MPa at 0.5 Hz followed with a resting phase at atmospheric pressure for one to sixty days.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The construct of claim 1 wherein said culturing step is performed under cyclic hydrostatic pressure for five to eight days.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The construct of claim 1 wherein the resting phase is for one to sixty days.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The construct of claim 1, wherein said culturing step is performed under the cyclic hydrostatic pressure of 3MPa at 0.5Hz for six days followed by twelve days of the resting phase.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>The construct of claim 1, wherein said integration layer comprises a copolymer of polyethylene glycol and collagen, collagen, fibrin, agarose, alginate, chitin, polylactic acid, polyglycolic acid, a co-polymer of polylactic acid and polyglycolic acid or a copolymer of collagen and fibrin.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The construct of claim 1 wherein said sponge matrix is prepared from Type I collagen.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>The construct of claim 1 wherein said seeded device is cultured under reduced oxygen concentration of less than 20% saturation.</claim-text></claim></claims><claims mxw-id="PCLM56983369" lang="FR" load-source="patent-office"><!-- EPO <DP n="41"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Construction multicouche implantable préparée par un procédé comprenant les étapes suivantes:
<claim-text>(a) procurer une structure multicouche implantable comprenant:
<claim-text>(i) une couche d'intégration;</claim-text>
<claim-text>(ii) une couche de support cellulaire comprenant une matrice spongieuse et étant liée de façon opérationnelle à la couche d'intégration;</claim-text></claim-text>
<claim-text>(b) introduire une solution comprenant des chondrocytes en suspension dans ladite structure multicouche afin de créer un dispositif ensemencé; et</claim-text>
<claim-text>(c) cultiver ledit dispositif ensemencé dans des conditions comprenant une pression hydrostatique cyclique suivie d'une phase de repos à la pression atmosphérique.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Construction selon la revendication 1, comprenant en outre:
<claim-text>(iii) une couche de protection isolant une surface extérieure de la couche de support cellulaire, la couche de protection étant liée de façon opérationnelle à la couche de support cellulaire et à la couche d'intégration.</claim-text></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Construction selon la revendication 1, dans laquelle la pression hydrostatique cyclique est comprise entre 0,01 et 10 MPa à 0,5 Hz.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Construction selon la revendication 1, dans laquelle ladite solution est une solution aqueuse de collagène de type I.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Construction selon la revendication 1, dans laquelle ladite solution est un sol-gel.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Construction selon la revendication 5, dans laquelle ledit sol-gel est au moins partiellement gélifié.<!-- EPO <DP n="42"> --></claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Construction selon l'une quelconque des revendications précédentes, dans laquelle lesdits chondrocytes sont substantiellement immobilisés à l'intérieur dudit dispositif.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Construction selon la revendication 1, dans laquelle ladite étape de culture conduit à une activation desdits chondrocytes pour élaborer des produits géniques associés à une matrice extracellulaire.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>gaz Construction selon la revendication 1, dans laquelle ladite étape de culture est effectuée sous la pression hydrostatique cyclique comprise entre 0,5 et 5 MPa à 0,5 Hz suivie d'une phase de repos à la pression atmosphérique de un à soixante jours.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Construction selon la revendication 1, dans laquelle ladite étape de culture est effectuée sous une pression hydrostatique cyclique pendant cinq à huit jours.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Construction selon la revendication 1, dans laquelle la phase de repos a une durée de un à soixante jours.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Construction selon la revendication 1, dans laquelle ladite étape de culture est effectuée sous la pression hydrostatique cyclique de 3 MPa à 0,5 Hz pendant six jours suivie de douze jours de la phase de repos.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Construction selon la revendication 1, dans laquelle ladite couche d'intégration comprend un copolymère de polyéthylène glycol et de collagène, du collagène, de la fibrine, de l'agarose, de l'alginate, de la chitine, de l'acide polylactique, de l'acide polyglycolique, un copol êre de l'acide polylactique et de l'acide polyglycolique ou un copolymère de collagène et de fibrine.<!-- EPO <DP n="43"> --></claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Construction selon la revendication 1, dans laquelle ladite matrice spongieuse est préparée à partir de collagène de type I.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Construction selon la revendication 1, dans laquelle ledit dispositif ensemencé est cultivé sous une concentration d'oxygène réduite de moins de 20 % de saturation.</claim-text></claim></claims><drawings mxw-id="PDW16671532" load-source="patent-office"><!-- EPO <DP n="44"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="117" he="166" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="45"> --><figure id="f0002" num="2A"><img id="if0002" file="imgf0002.tif" wi="136" he="132" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="46"> --><figure id="f0003" num="2B"><img id="if0003" file="imgf0003.tif" wi="135" he="136" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="47"> --><figure id="f0004" num="3A"><img id="if0004" file="imgf0004.tif" wi="139" he="82" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="48"> --><figure id="f0005" num="3B"><img id="if0005" file="imgf0005.tif" wi="143" he="79" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="49"> --><figure id="f0006" num="4"><img id="if0006" file="imgf0006.tif" wi="132" he="144" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
